Please login to the form below

Not currently logged in
Email:
Password:

GlycoVaxyn appoints Gerd Zettlmeissl as chairman

He will join the Swiss vaccines company in June

Swiss vaccines company GlycoVaxyn has appointed Gerd Zettlmeissl as chairman of the board of directors with effect from June, when he will take over from Michel Greco.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company," Greco said.

"Having chaired the board for more than seven years, I will work very closely with Gerd to ensure a smooth transition," he added.

Zettlmeissl has more than 20 years of experience in developing and commercialising vaccines and spent almost 10 years in executive positions at Intercell.

He served first as its chief operating officer from 2001 to 2005 and then as CEO from 2005 until May  2011.

Prior to joining Intercell, Zettlmeissl served as international head of industrial and quality operations at Chiron Vaccines, and managing director of Chiron Behring GmbH & Co.

He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.

6th March 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics